For Discovery’s Surfaxin, Another Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
Discovery Labs delays the commercial launch of its RDS drug Surfaxin until 2Q 2013, but continues to look for an international partner for the rest of its pipeline. The company assures investors that the delay is not indicative or safety or efficacy problems.